A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of α-difluoromethylornithine in subjects with previous history of skin cancer

Cancer Prevention Research

Volumn 3, Issue 1, 2010, Pages 35-47

  Bailey, Howard H ^a   Kim, Kyungmann ^a   Verma, Ajit K ^a   Sielaff, Karen ^a   Larson, Paul O ^a   Snow, Stephen ^a   Lenaghan, Theresa ^a   Viner, Jaye L ^d   Douglas, Jeff ^a,e   Dreckschmidt, Nancy E ^a   Hamielec, Mary ^a   Pomplun, Marcy ^a   Sharata, Harry H ^b   Puchalsky, David ^c   Berg, Eric R ^c   Havighurst, Thomas C ^a   Carbone, Paul P ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c Meriter Clinic   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; EFLORNITHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RETINOL; SUNSCREEN; ANTINEOPLASTIC AGENT; ORNITHINE DECARBOXYLASE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; AUDIOMETRY; BASAL CELL CARCINOMA; CANCER PREVENTION; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OTOTOXICITY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; DRUG ANTAGONISM; DRUG EFFECT; HEARING; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; AUDIOMETRY; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DOUBLE-BLIND METHOD; EFLORNITHINE; FEMALE; HEARING; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ORNITHINE DECARBOXYLASE; SKIN NEOPLASMS;

EID: 77649195334     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0096     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Chen J, Fleisher AB, Jr., Smith ED, et al. Cost of non-melanoma skin cancer treatment in the United States. Dermatol Surg 2001;27: 1035-1038.
3. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000;143:513-9.
4. Ramsay HM, Reece SM, Fryer AA, et al. Seven-year prospective study of non-melanoma skin cancer incidence in UK renal transplant recipients. Transplantation 2007;84:437-9.
5. Bath-Hextall FJ, Leonardi-Bee J, Somchand N, Webster AC, Delitt J, Perkins W. Interventions for preventing non-melanoma skin cancers in high-risk groups. Cochrane Database Syst Rev 2007, Issue 4. Art. No.: CD005414.
6. Boukamp P. Non-melanoma skin cancer: what drive tumor development and progression. Carcinogenesis 2005;26:1657-67.
7. van der Pols JC, Williams GM, Pandeya N, et al. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006;15:2546-8.
8. Tangrea JA, Edwards BK, Taylor PR, et al. Long term therapy with low-dose isotretoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretoin-basal cell study group. J Natl Cancer Inst 1992;5:328-32.
9. Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997;6:949-56.
10. Levine N, Moon TE, Cartmel B, et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997;6:957-61.
11. Frieling UM, Schaumberg DA, Kupper TS, Muntwyler J, Hennekens CH. A randomized, 12-year primary-prevention trial of β carotene supplementation for non-melanoma skin cancer in the physician's health study. Arch Dermatol 2000;136:179-84.
12. Duffield-Lillico AJ, Slate EH, Reid ME, et al. Selenium supplementation and secondary prevention of non-melanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003;95:1477-81.
13. O'Brien TG, Simsiman RC, Boutwell RK. Induction of the polyamine biosynthetic enzymes in mouse epidermis by tumor-promoting agents. Cancer Res 1975;35:1662-70.
14. Morgan DML. Polyamines: an introduction. Methods Mol Biol 1998; 79:3-30.
15. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 1988;48:759-74.
16. Meyskens FL, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:945-51.
17. Verma A, Lowe N, Boutwell R. Induction of mouse epidermal ornithine decarboxylase activity and DNA synthesis by ultraviolet light. Cancer Res 1979;39:1035-40.
18. Verma AK, Shapas BG, Rice HM, Boutwell RK. Correlation of the inhibition by retinoids of tumor promoter-induced mouse epidermal ornithine decarboxylase activity and of skin tumor promotion. Cancer Res 1979;39:419-25.
19. Love RR, Carbone PP, Verma AK, et al. Randomized phase I chemoprevention dose-seeking study of α-difluoromethylomithine. J Natl Cancer Inst 1993;85:732-7.
20. Love RR, Jacoby R, Newton MA, et al. A randomized, placebo-controlled trial of low-dose α-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epid Bio Prev 1998;7:989-92.
21. Meyskens FL, Gerner EW, Emerson S, et al. A randomized double-blind placebo controlled phase IIb trial of difluoromethylornithine for colon cancer prevention. J Natl Cancer Inst 1998;90:1212-8.
22. Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, et al. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 2006;176:500-4.
23. Messing EM, Love RR, Tutsch KD, et al. Low-dose difluoromethylornithine and polyamine levels in human prostate tissue. J Natl Cancer Inst 1999;16:1416-7.
24. Simoneau AR, Gerner EW, Phung M, McLaren CE, Meyskens FL. α-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial. J Natl Cancer Inst 2001;93:57-9.
25. Vlastos AT, West LA, Atkinson EN, et al. Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. Clin Cancer Res 2005;11: 390-6.
26. Fabian CJ, Kimler BF, Brady DA, et al. A phase II breast cancer chemoprevention trial of oral α-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 2002;8: 3105-17.
27. Carbone PP, Douglas JA, Larson PO, et al. Phase I chemoprevention study of piroxicam and α-difluoromethylornithine. Cancer Epid Bio Prev 1998;7:907-12.
28. Meyskens FL, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:9-11.
29. Verma AK, Loprinzi CL, Boutwell RK, Carbone PP. In vitro induction of human skin ornithine decarboxylase by the tumor promoter 12-Otetradecanoylphorbol-13-acetate. J Natl Cancer Inst 1985;75:85-90.
30. Carbone PP, Douglas JA, Thomas J, et al. Bioavailability study of oral liquid and tablet forms of α-difluoromethylornithine. Clin Cancer Res 2000;6:3850-4.
31. Shotland LI, Ondrey FG, Mayo KA, Viner JL. Recommendations for cancer prevention trials using potentially ototoxic Agents. J Clin Oncol 2001;19:1658-63.
32. Greenberg ER, Baron JA, Stukel TA, et al. A clinical trial of β carotene to prevent basal-cell and squamous-cell cancers of the skin. N Engl J Med 1990;323:789-95.
33. Kabra P, Lee HK, Lubich WP, Marton LJ. Solid-phase extraction and determination of dansyl derivatives of unconjugated and acetylated polyamines by reversed-phase liquid chromatography: improved separation systems for polyamines in cerebral spinal fluid, urine and tissue. J Chrom 1986;380:19-32.
34. Rubin AI, Chen EH, Ratner D. Current concepts basal cell carcinoma. N Engl J Med 2005;353:2262-9.
35. Tang JY, So P-L, Epstein EH, Jr. Novel Hedgehog pathway targets against basal cell carcinoma. Toxicol Appl Pharmacol 2007;224: 257-64.
36. Tang X, Kim AL, Feith DJ, et al. Ornithine Decarboxylase is a target for chemoprevention of basal and Squamous cell carcinomas in Ptch+/- mice. J Clin Invest 2004;13:867-75.